Novartis India launches Pluvicto for prostate cancer treatment

Key facts

• Novartis India launched Pluvicto, a precision radiotherapy for the treatment of prostate cancer.
• Pluvicto is the first regulatory authority-approved radioligand therapy in India for patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
• The therapy is designed to precisely target prostate cancer cells while minimising exposure to healthy tissues.
• Pluvicto introduces a new treatment approach specifically for metastatic prostate cancer.
• The treatment will be made available through select hospitals and nuclear medicine centres across India.